There are many instances where a pharmaceutical company has taken over, or partnered, on the basis of initial evidence even at the preclinical stage. Have a quick read of fiercebiotech. You could say that Viralytics Cavatak wasn’t really proven but still had a good TO premium.
But I hope that IMU doesn’t go down that route, there’s much more potential value in longer term licensing as and when there’s proper evidence of efficacy.
There are many instances where a pharmaceutical company has...
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.8¢ |
Change
-0.001(2.56%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 3.8¢ | 3.9¢ | 3.8¢ | $423.0K | 11.10M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 141633 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 1926108 | 10 |
View Market Depth
| Last trade - 16.10pm 25/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
